Seqiris completes $156 million expansion for influenza vaccine production
The pre-filled syringe line has already received FDA approval
Seqiris has announced the completion of an expansion to the company’s manufacturing facility in Holly Springs, North Carolina, US, supporting the formulation and fill-finish of its cell-based influenza vaccines in pre-filled syringes for global communities.
Seqiris is a global leader in influenza prevention, and the expansion will enhance the site’s ability to respond to an influenza pandemic. The expansion began in 2018, and will support over 80 additional highly skilled jobs in the Holly Springs community.
“According to the World Health Organization (WHO), seasonal influenza can lead to up to 650,000 deaths globally each year,” said Steve Marlow, General Manager, Seqirus. “As one of the world's leading influenza vaccine manufacturers, we’re continuously looking for opportunities to advance capabilities and support efficient, sustained supply of new and existing technologies. Today’s milestone is evidence of that commitment.”
The new pre-filled syringe line has received FDA approval, and will support influenza vaccine production for the 2022/23 Northern Hemisphere season and beyond. The expanded manufacturing facility and new pre-filled syringe line will allow Seqiris to increase its capacity to supply the US market with FLUCELVA X QUADRIVALENT (inf luenza vaccine), the first and only cellbased quadrivalent inf luenza vaccine in the US for individuals six months of age and older.
“As demand for differentiated inf luenza vaccines grows, it is paramount that we expand our manufacturing capacity,” said Dave Ross, Vice President, North America Commercial Operations at Seqirus. “This new line gives us the ability to more efficiently streamline our production process, allowing us to better meet the needs of our customers and, in turn, better meet the needs of public health.”
The Holly Springs manufacturing facility is the largest cell-based inf luenza vaccine producer in the world, and the first of its kind in the US. The facility expansion enhances the site’s regular seasonal inf luenza vaccine production, as well as to surge production to respond to a potential influenza pandemic.